---
schema_version: "secwatch.filing_event.v1"
accession: "0001099800-26-000023"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-14T23:49:29.582096+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Edwards Lifesciences appoints Theodora Mistras as CFO, effective May 29, 2026

## Summary
- Theodora Mistras appointed CFO effective May 29, 2026, succeeding Scott Ullem (announced October transition).
- Compensation: $925K base salary, $2.013M sign-on bonus (pro-rata clawback within 24 months), $8M RSUs (vesting over 3 years).
- Mistras was previously CFO of Viatris (since March 2024) and held senior roles at Citigroup and Goldman Sachs in healthcare IB.
- She is eligible for severance of at least 1x base salary plus 1x target bonus, pro-rated bonus, and $50K outplacement.

## SEC filing metadata
- accession: 0001099800-26-000023
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000023/0001099800-26-000023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000023/ew-20260502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001099800-26-000023
- JSON: https://secwatch.observer/filing/0001099800-26-000023.json
- Plain text: https://secwatch.observer/filing/0001099800-26-000023.txt

## Key facts
- Executive change
  Theodora Mistras was appointed as Corporate Vice President, Chief Financial Officer at Edwards Lifesciences Corp.
  - Action: appointed
  - Role: Corporate Vice President, Chief Financial Officer
  source text: On May 4, 2026, Edwards Lifesciences Corporation, a Delaware corporation (the “Company”), announced that Theodora Mistras has been appointed as the Corporate Vice President, Chief Financial Officer of the Company, effective May 29, 2026, to succeed Scott B. Ullem in that position.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1099800/000109980026000023/0001099800-26-000023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.